# Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis

> **NCT00728507** · PHASE2 · TERMINATED · sponsor: **Johns Hopkins University** · enrollment: 121 (actual)

## Conditions studied

- Tuberculosis

## Interventions

- **DRUG:** Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid
- **DRUG:** Isoniazid, Rifampin, Pyrazinamide, Ethambutol

## Key facts

- **NCT ID:** NCT00728507
- **Lead sponsor:** Johns Hopkins University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 121 (ACTUAL)
- **Why stopped:** Funding withdrawn
- **Last updated:** 2017-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00728507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00728507, "Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00728507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*